Medicines Co. (MDCO) Recovers; Evercore ISI's Raffat Says Data 'Looks Very Consistent and Durable'

November 15, 2016 1:10 PM EST
Get Alerts MDCO Hot Sheet
Price: $34.74 +5.85%

Rating Summary:
    15 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 36 | New: 11
Trade MDCO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Medicines Co. (NASDAQ: MDCO) has recovered sharply off intra-day lows as Ph 2 PCSk9 data presented at AHA. Shares are currently down 2.8% after trading down 8% earlier.

Evercore ISI's Umer Raffat said the data "looks very consistent and durable through day 180 (pts getting single injection had -43% LDL reduction at day 180)."

He notes he is getting several questions on 1 death in the 500 mg arm. He said it was a patient with extensive CAD history and multiple CV events in the past (note that exclusion criteria only selected out pts with MACE event within last 6 months). Also, 1 case of ALT>3ULN occurred in a patient escalating dose of statin.

Raffat notes the The discussant, Dr. Nordestgaard's review of data was very positive on the Ph 2 trial. "I would like to congratulate the investigators on this very very positive trial," Nordestgaard said.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Umer Raffat

Add Your Comment